The Pharma Letter55m
Eisai and Biogen gain FDA approval for monthly Leqembi
Eisai and Biogen have secured US Food and Drug Administration approval for a once-monthly intravenous maintenance dosing ...
The American Journal of Managed Care34m
FDA Approves New Maintenance Dosing for Lecanemab to Treat Early-Stage Alzheimer Disease
The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer ...
ENDPOINTS NEWS54m
Sage turns down Bio­gen's buy­out of­fer and will look at oth­er op­tions
Sage Therapeutics rejects Biogen's $469M buyout offer. CEO Barry Greene and board seek alternatives, with Goldman Sachs ...
precisionmedicineonline58m
Eisai, Biogen's Leqembi Receives FDA Approval for Chronic Alzheimer's Maintenance Treatment
With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.